title: Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
abstract: BACKGROUND
  The purpose of this study was to evaluate the prognostic value of circulating tumor cells (CTCs) expressing HER2 messenger RNA (mRNA) after the administration of adjuvant chemotherapy in women with operable breast cancer.
  
  
  METHODS
  HER2 mRNA-positive CTCs were detected by nested RT-PCR in the peripheral blood of 214 patients with stage I and II breast cancer after the completion of adjuvant chemotherapy.
  
  
  RESULTS
  HER2 mRNA-positive CTCs were detected in 45 (21%) patients. Adjuvant chemotherapy could eliminate HER2 mRNA-positive CTCs in 16 (30.2%) prechemotherapy-positive patients. Moreover, HER2 mRNA-positive CTCs were detected in eight (5%) of 161 prechemotherapy-negative patients. The detection of HER2 mRNA-positive CTCs after chemotherapy was associated with reduced disease-free interval (DFI) (P = 0.006) but not with overall survival (P = 0.2); this effect was mainly observed in node-negative patients (P = 0.04) and to a lesser extent in node-positive (P = 0.06). Multivariate analysis revealed that the detection of HER2 mRNA-positive CTCs was an independent predictive factor for DFI (hazard ratio 3.238, P < 0.0005).
  
  
  CONCLUSIONS
  The detection of HER2 mRNA-positive CTCs after the completion of adjuvant chemotherapy may provide clinically useful information concerning the efficacy of treatment and the prognosis of patients with operable breast cancer.
authors.affiliation: Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Apostolaki
authors.forename: M
authors.initials: M
authors.lastname: Perraki
authors.forename: A
authors.initials: A
authors.lastname: Pallis
authors.forename: V
authors.initials: V
authors.lastname: Bozionelou
authors.forename: S
authors.initials: S
authors.lastname: Agelaki
authors.forename: P
authors.initials: P
authors.lastname: Kanellou
authors.forename: A
authors.initials: A
authors.lastname: Kotsakis
authors.forename: E
authors.initials: E
authors.lastname: Politaki
authors.forename: K
authors.initials: K
authors.lastname: Kalbakis
authors.forename: A
authors.initials: A
authors.lastname: Kalykaki
authors.forename: L
authors.initials: L
authors.lastname: Vamvakas
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
authors.forename: D
authors.initials: D
authors.lastname: Mavroudis
mesh_terms: D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating; D011379:Prognosis; D012333:RNA, Messenger / Q000097:blood*; D012334:RNA, Neoplasm / Q000097:blood*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D012333:RNA, Messenger; D012334:RNA, Neoplasm; D018719:Erb-b2 Receptor Tyrosine Kinases